An observational study in Dementia, Dementia Alzheimers and Dementia, Vascular, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University of Michigan · Observational
Among 1,049 studies in Dementia with a site in United States — 211 open to participants now, 278 under way, 15 of them phase 3. Dementia · United States.
Among the 1,049 studies in Dementia with a site in United States, this one is the 66th largest by enrollment of the 199 observational ones, is one of 51 that started in 2018, is one of 199 observational ones, and was the 410th registered.
2,372 studies on the registry are indexed under Dementia; 574 are open to participants now.
This study's enrollment of 634 is above the median of 256 across 553 observational studies indexed under Dementia.
Browse Dementia studies →211 of the 1,049 studies in Dementia with a site in United States are open now, in 12 countries. Each count lists the studies.
Of the 381 Dementia studies recruiting now, 242 (64%) set no upper age limit and 25 (7%) stop at 75 or younger; 16 take children under 18; 163 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →1,049 studies; the count open now beside each. This study's row is marked.
First in 1981; this study’s year is marked. 51 started in 2018.
Median enrollment 92 across the 845 interventional studies, 200 across the 199 observational. Of the 712 that completed or were terminated, 308 (43%) have results posted.
191 of 1,049 have an industry lead sponsor. The 10 most frequent:
University of Michigan is the lead sponsor of 1,506 studies on the registry; 192 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 133 (79%) have results posted.
University of Michigan has 9 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
109 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06147999First Institute of All MedicinesImpact of a Biophoton Therapy on Patients With Brain Disorders | 2026-11-08 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
Among the 1,049 studies in Dementia with a site in United States, from their registry updates:
The Mexican American population in the U.S. is rapidly growing and aging. This project seeks to determine the prevalence and outcomes of cognitive impairment and dementia in Mexican Americans. It also seeks solutions to help patients with cognitive impairment and dementia and their caregivers get the resources they need.
Hispanic/Latinos will comprise more than 30% of the U.S. population by mid-century, and Mexican Americans account for the largest share of this growing segment of society. This proposal aims to use door-to-door surveillance in Nueces County, Texas, a non-immigrant, bi-ethnic community, to determine the prevalence and trajectory over time of cognitive impairment and dementia in Mexican Americans and non Hispanic whites. The study will elucidate the mechanisms that explain the hypothesized ethnic disparity in Alzheimer's disease and Alzheimer-related dementias by evaluating the roles of vascular disease risk factors, educational attainment and socio-economic status among others. This research will also delve deeply into the differences in informal caregiving for Mexican American and non Hispanic whites with cognitive impairment and dementia. Caregiver burden and mental and physical health of caregivers will be examined toward efforts to develop interventions that build resilience in caregivers. A novel ability of this population-based study is to examine community resources for both patients and caregivers, and how these provisions differ by ethnicity. Using a rigorous mixed methods approach the study will identify the gap between available resources and needs for those with cognitive impairment and dementia. In this way we will be well positioned to propose ethnic-specific testable interventions that promote mental and physical health for those with cognitive impairment and dementia, as well as for those family members who provide the care. This research will therefore lead to improved well-being, autonomy and outcomes among those with cognitive impairment and dementia and their caregivers. The investigative team members have conducted research in this community for 20 years and are experts in Mexican American culture and health, cognitive impairment and dementia, epidemiologic methods, community needs assessment and health behavior research. As the Mexican American population continues its tremendous growth and aging it is vitally important to better understand the prevalence and outcomes of cognitive impairment and dementia in this population, and to rapidly develop interventions that address the burden of these common conditions in Mexican American adults, families, and communities.
Residents of Nueces County, Texas
Inclusion Criteria:
1.65 years of age or older 2. \< 26 3. Nueces County resident at least 6 months a year 4. English or Spanish speaking 5. Community dwelling or nursing home
Exclusion Criteria: none
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with MoCA \<26
Other: No interventions
Primary caregivers of subjects
Other: No interventions
No intervention
Prevalence of mild cognitive impairment and dementia in Mexican Americans and non Hispanic whites
Prevalence estimates
Time frame: 2 year data collection
Trajectory of cognitive function in Mexican Americans and non Hispanic whites
Change in cognitive function among subjects entered at baseline
Time frame: 2 year follow-up after baseline
Caregiver outcomes and changes over time
Comparative caregiver outcomes among Mexican Americans and non Hispanic whites
Time frame: 4 years
Needs and community available resources for cognitive impairment
An asset map and determination of needs
Time frame: 2 years
Plan to share: Undecided — Data sharing plan conforms to NIH rules.
Ran from Apr 2018 to primary completion in Apr 2026, 96 months.
Of 271 non-industry observational studies under Dementia, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 202. This study's 96 months is above that.
Counting every sponsor, half of 293 studies reached it within 67 months; a quarter within 29 and three quarters within 188.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.